Skip to main content

Todd Golub, Jutta Heim, Olli Kallioniemi, Achim Feurer, Curt LaBelle, Paul Herring, Anthony Martin, Wendell Wierenga, Mary Callan


Todd Golub has been named to the scientific advisory board of Ardais of Lexington, Mass. Golub is director for cancer genomics at the Whitehead/MIT Center for Genome Research, and pediatric oncologist at Dana-Farber Cancer Institute. Golub has an MD from the University of Chicago Pritzker School of Medicine and is an investigator with the Howard Hughes Medical Institute.

Jutta Heim and Olli Kallioniemi have joined the scientific advisory board of


, a Dutch microarray technology startup. Heim heads the lead discovery center of

Novartis. Kallioniemi

is professor of medical biotechnology at the VTT Technical Research Center of Finland. Previously, he was head of the translational genomics branch at the National Human Genome Research Institute at NIH.

Achim Feurer, 40, has been named director of medicinal chemistry for Heidelberg, Germany-based Graffinity Pharmaceuticals. Feurer was project manager for the medicinal chemistry department of the pharmaceutical unit of Bayer in Wuppertal, Germany. Graffinity combines microarrays and label-free detection systems to assay compound-protein interactions.

Curt LaBelle joins the health care venture capital firm Tullis-Dickerson & Co. of Greenwich, Conn., as senior associate. LaBelle was previously at Convergent Ventures of Los Angeles. LaBelle has an MD/MBA from Columbia University and a BS in economics from Brigham Young University.

Agilent Technologies created a new scientific advisory board and appointed: Paul Herring, director of corporate research at Novartis International; Anthony Martin, president and CEO of Molecular Probes; Mark Skolnick, founder of Myriad Genetics; and Wendell Wierenga, CEO of Syrrx.

Mary Callan, former director of business development at Exelixis, has been appointed vice president of business development at Morphotek of Philadelphia.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.